You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

CAPECISP+TRAS

Cancer Type: Gastrointestinal, Esophagus, Gastric / Stomach      Intent: Palliative
Regimen Category: Evidence-Informed
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
ODB - General Benefit
    capecitabine

You might also be interested in